Clinical Trial

Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy

Study acronym: POPB-TOX
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
In children population with obstetrical brachial plexus palsy (OBPP), shoulder musculoskeletal deformity is the main cause of morbidity, with a loss of range of shoulder motion, pain and a reduction in social participation. Some uncontrolled studies shows that early injections of botulinum toxin (BTI) in the internal shoulder rotator muscles (which cause the deformity) are one of the most promising treatment for the prevention of bony deformity. The main objective of this study will be the evaluation of the effectiveness of BTI in the internal shoulder rotator muscles at the age of 12 months in preventing an increase in posterior subluxation of the glenohumeral joint in babies with OBPP (evaluated at the ages of 11 months and 18 months), compared to the Sham group.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-06-23; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2018-09-28
Trial Details
NCT Number NCT03198702
Lead Sponsor University Hospital, Brest
Conditions Obstetrical Brachial Plexus Palsy
Enrollment 62 participants
Start Date 2018-05-17
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-20